$ 21.99 · 4.6 (601) · In stock
Triple-negative breast cancer (TNBC) has a worse prognosis and remains the most challenging breast cancer subtype to treat. This is largely related to the heterogeneity of this disease and the lack of reliable oncological targets. In this review, we discuss the current standard-of-care treatment options for metastatic TNBC, including recent advances with the use of immunotherapy, PARP inhibitors and antibody-drug conjugates. This review also explores new agents and novel combinations arising in the field for the treatment of advanced TNBC.
Current Oncology January 2024 - Browse Articles
Current Oncology, Free Full-Text, Skin Tone Construction Paper
Current Oncology, Free Full-Text
Cancer Reports - Wiley Online Library
Overall Survival with Ribociclib plus Letrozole in Advanced Breast
Home - NCCS - National Coalition for Cancer Survivorship
NEJM on X: Get the latest research in Hematology/Oncology reports
Current Oncology, Free Full-Text
Current Oncology, Free Full-Text, bronstein méier resultado